文献速递皮肤肿瘤

LVR01减毒沙门氏菌新辅助瘤内治疗联合化疗的黑色素瘤临床前评价

Preclinical Evaluation of LVR01 Attenuated Salmonella as Neoadjuvant Intralesional Therapy in Combination with Chemotherapy for Melanoma Treatment.
PubMed 文献 · J Invest Dermatol · 2021-10-15

本研究在B16F1黑色素瘤小鼠模型中评估LVR01减毒沙门氏菌作为新辅助瘤内治疗联合达卡巴嗪化疗的效果。LVR01于化疗开始前1天单次瘤内注射,达卡巴嗪连续3天腹腔给药。该联合方案延缓肿瘤生长并延长总生存期,显示强协同抗肿瘤效应。

要点

  • LVR01单次瘤内注射联合达卡巴嗪可延缓肿瘤生长并延长总生存期
  • 达卡巴嗪致次级淋巴器官细胞显著减少,沙门氏菌部分恢复并增强活化细胞毒性细胞
  • LVR01诱导的强烈炎性肿瘤微环境可能驱动全身免疫再激活

核心结论

  • LVR01作为新辅助瘤内治疗联合达卡巴嗪在临床前黑色素瘤模型中显示强协同抗肿瘤效应,具临床转化潜力。

研究设计与样本

  • 临床前黑色素瘤模型研究,使用B16F1黑色素瘤荷瘤小鼠。
  • 达卡巴嗪连续3天腹腔给药,LVR01于化疗开始前1天单次瘤内注射。

主要发现

  • 联合治疗延缓肿瘤生长并延长总生存期,显示强协同抗肿瘤效应。
  • 达卡巴嗪导致次级淋巴器官细胞显著减少,LVR01部分恢复该减少并尤其增强活化细胞毒性细胞区室。
  • LVR01诱导的强烈炎性肿瘤微环境可能是全身免疫再激活的原因。

临床怎么用

  • 提示LVR01新辅助瘤内联合化疗可能成为提升黑色素瘤化疗效果的策略,但尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment of malignant melanoma has improved in the last few years owing to early detection and new therapeutic options. Still, management of advanced disease remains a challenge because it requires systemic treatment. In such cases, dacarbazine-based chemotherapy has been widely used, despite low efficacy. Neoadjuvant therapies emerge as alternative options that could help chemotherapy to achieve increased benefit. In this work, we evaluate LVR01, an attenuated Salmonella enterica serovar typhimurium, as neoadjuvant intralesional therapy in combination with dacarbazine in a preclinical melanoma model. B16F1 melanoma‒bearing mice received intraperitoneal administration of dacarbazine for 3 consecutive days. LVR01 treatment, consisting of one single intratumoral injection, was applied 1 day before chemotherapy began. This therapeutic approach retarded tumor growth and prolonged overall survival, revealing a strong synergistic antitumor effect. Dacarbazine induced a drastic reduction of secondary lymphoid organ cellularity, which was partially restored by Salmonella, particularly potentiating activated cytotoxic cell compartments. Systemic immune reactivation could be a consequence of the intense inflammatory tumor microenvironment induced by LVR01. We propose that the use of LVR01 as neoadjuvant intralesional therapy could be considered as an interesting strategy with close clinical application to boost chemotherapy effect in patients with melanoma.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Chilibroste S, Mónaco A, Plata MC, et al. Preclinical Evaluation of LVR01 Attenuated Salmonella as Neoadjuvant Intralesional Therapy in Combination with Chemotherapy for Melanoma Treatment. J Invest Dermatol. 2021. PMID: 34662563. doi:10.1016/j.jid.2021.08.442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。